medigraphic.com

2008, Number 3

<< Back Next >>

Anales de Radiología México 2008; 7 (3)

Medios de contraste paramagnéticos

Rodríguez NP, Dena EEJ, Basile LR, Fuentes GM, Olhagaray RBM, Piedras MA

Language: Spanish
References: 28
Page: 191-198
PDF size: 717.20 Kb.


ABSTRACT

Introduction: In 1983 Weinmann and colleagues created the first paramagnetic contrast medium (agent) with good results: the Gd-DTPA (Magnevist®) Bayer Schering Pharma, Berlin, Universidad libre de Berlin (Félix MD) and Hammersmith Hospital (R. Steiner D), afterwards, another paramagnetic contrast medium appeared, which is actively used worldwide.
Discussion: General features of the paramagnetic contrast medium existing in the market are shown, for both with the extracellular paramagnetic contrast medium, the “Blood Pool” contrast agents, the super paramagnetic iron oxide, as well as particles: SPIO (small super paramagnetic iron oxide), USPIO (ultra-small super paramagnetic iron oxide) VSPIO (very ultra-small super paramagnetic iron oxide). Also we present the recommendations in the administration of contrast agents, as well as the prevention of Nephrogenic Systemic Fibrosis.
Conclusions: Since the establishment by Weinmann et al. the first paramagnetic contrast agent in 1983, the Gd-DTPA (Magnevist ®) Bayer Schering Pharma, contrast agents are used annually in one third of 50 million study.


REFERENCES

  1. Taveras JM, Flores E, Boleaga B, Naidich TP, Oulton CA, Staut CCV. Avances de la resonancia magnética en Neurorradiología. Edimarket; 1995.

  2. Hesseling JR, Scwaighofer BW, Klein MV, Wesbey G. Diagnostic yield of routine use of Gd-DTPA for brain MRI. In: Bydder G, Felix R, Buecheler E, Drayer BP, et al. (eds.). Contrast Media in MRI. Bussum. Medicom Europe; 1990, p. 80-8.

  3. Schoerener W, Schubeus P, Hein T, Neumann K, et al. Contrast. enhanced MRI of intracranial meningiomas. In: Bydder G, Felix R, Buecheler E, Drayer BP, et al. (eds.). Contrast Media in MRI. Bussum. Medicos Europe; 1990, p. 97-108.

  4. Weinmann HJ, Press WR, Raduechel B, et al. Characteristics of Gd-DTPA and new derivates. In: Byder G, Felix R, Buecheler E, Drayer BP, et al. (eds.). Contrast Media in MRI. Bussum. Medicos Europe; 1990, p. 15-17.

  5. Dena EEJ, Rodríguez NP. Medios de contraste intravasculares en imagenología; pasado, presente y futuro. Segunda parte (2). Rev Mex Radiol 1996; 50: 63-70.

  6. Dawson P, Cosgrove DO, Grainger RG. Section II MR Contrast Agents. Textbook of Contrast Media. Isis Medical Media Ltd; 1999. p. 251-450.

  7. Gd DTPA-Magnevist-Monografía del producto-Bayer Schering Pharma.

  8. Gd-DTPA-Magnitrast-Monografía del producto Justesa Imagen Mexicana.

  9. Gd DOTA-Monografía del producto-Dotarem-Guerbet.

  10. Gd DTPA-Monografía del producto-BMA Omniscan-Amersham.

  11. Gd DTPA-Monografía del producto-BMEA Optimark-COVIDIEN.

  12. Gadobutrol-Gadovist-Monografía del producto-Bayer Schering Pharma.

  13. Grossman RI, Rubin DL, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: A comparison of OptiMARK (Gd-DTPABMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000; 35: 412-19.

  14. Runge VM, Nelson KL. Agentes de contraste. En: Stark DD, Bradley WG (ed.). Resonancia Magnética. Harcourt. Mosby, Inc.; p. 257-75.

  15. Dena EEJ, Rodríguez NP y cols. Medios de contraste en resonancia magnética. En: Dena EEJ, Rodríguez NP, Perez DMA (eds.). Manual de Técnicas en Radiología e Imagen. Edit. Trillas; 1998, p. 207-9.

  16. Poellinger A, et al. Magnetic resonance coronary angiography: Experimental Results with a Monomer-stabilized, Very Small Superparamagnetic Iron Oxide Particle (VSOP) Blood Pool Contrast Medium. 87 th Scientific Assembly And Annual Meeting RSNA; 2001, p. 518.

  17. Cardiovascular Imaging. Hope surrounds research on MR blood pool agents. Diagnostic Imaging America; 2000.

  18. Welmers A, et al. Three-dimensional visualization in staging and diagnosis of rinary bladder cancer using high-resolution MRI. 87th Scientific Assembly And annual Meeting. RSNA; 2001, p. 180.

  19. Gili J. Cap.12 Substancias de contraste en IRM.12.1-12.8. en Gili J. Introducción Biofísica a la Resonancia Magnética en Neuroumagen. Memorias del XIV Congreso Iberolatinoamericano de Neurorradiología. SILAN; 2002.

  20. 87th Scientific Assembly And Annual Meeting. November 25-30. RSNA 2001; 518.

  21. Sociedad Europea de Radiología Urogenital (ESUR). versión 4.0.

  22. ACR Guidance Document for safe RM practice. AJR 2007; 188. www.fda.gov/cder/drug/advisory/gadolinium_agents.html www.mhra.gov.uk.

  23. Broome DR, Girguis MS, Baron PW, Cottrell AC, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188(2): 586-92.

  24. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-7.

  25. Khurana A, Runge VM, Narayanan M, Greene JF Jr, et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Invest Radiol 2007; 42(2): 139-45.

  26. Lim YL, Lee HY, Low SC, Chan LP, et al. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007.

  27. NSF Incidence Declining as Studies Continue. RSNA News 2008; 18(7).

  28. Little FF, Worth HM. Anafilaxis. In: Irwin RS, Rippe JM (eds.). Medicina Intensiva. Edit. Marban; 2006, p. 2288.




2020     |     www.medigraphic.com